Launch and pricing of EUR2.2bn bond issues

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

AstraZeneca launches and prices bond issues of €2,200,000,000

AstraZeneca PLC, rated A3 (stable outlook) by Moody's and A- (stable outlook) by Standard & Poor's, announces today the successful pricing of euro medium term notes in an aggregate principal amount of €2,200,000,000 (the "Notes"), consisting of three tranches:

· €500,000,000 of 5-year fixed rate notes with a coupon of 0.25%

· €900,000,000 of 8-year fixed rate notes with a coupon of 0.75%

· €800,000,000 of 12-year fixed rate notes with a coupon of 1.25%

The proceeds of the issues will be used for general corporate purposes, which may include repayment of debt.

The Notes are being issued under the U.S.$5,000,000,000 Euro Medium Term Note Programme of AstraZeneca PLC.

The Notes will be issued to institutional investors outside the US in accordance with Regulation S of the U.S. Securities Act of 1933, as amended. The Notes will be admitted to listing on the UK Listing Authority's Official List and to trading on the London Stock Exchange's regulated market.

A C N Kemp

Company Secretary

9 May 2016

Notes to editors

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com